{"id":3334,"date":"2016-08-15T18:21:18","date_gmt":"2016-08-15T18:21:18","guid":{"rendered":"http:\/\/blogs.sld.cu\/oserranob\/?p=3334"},"modified":"2016-08-15T18:35:21","modified_gmt":"2016-08-15T18:35:21","slug":"seleccion-de-pacientes-para-nueva-terapia-oncologica","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2016\/08\/15\/seleccion-de-pacientes-para-nueva-terapia-oncologica\/","title":{"rendered":"Selecci\u00f3n de pacientes para nueva terapia oncol\u00f3gica"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2016\/08\/2016-08-15-immunooncology.jpg\"><img loading=\"lazy\" class=\"alignleft size-full wp-image-3343\" style=\"border-width: 1px;margin: 5px\" src=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2016\/08\/2016-08-15-immunooncology.jpg\" alt=\"2016 08 15 immunooncology\" width=\"85\" height=\"67\" \/><\/a>Las tecnolog\u00edas \u00f3micas son cruciales para seleccionar los pacientes oncol\u00f3gicos que pueden beneficiarse de los inhibidores que bloquean las v\u00edas inmunitarias relacionadas con <a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/gene\/1493\" target=\"_blank\">CTLA-4<\/a> y <a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/gene\/5133\" target=\"_blank\">PD-1<\/a>. El tema es revisado en Dijkstra KK, Voabil P, Schumacher TN, Voest EE.\u00a0 <a title=\"Texto completo en ingl\u00e9s\" href=\"http:\/\/oncology.jamanetwork.com\/article.aspx?articleid=2542339\" target=\"_blank\">Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors<\/a>. JAMA Oncol. 2016; doi:10.1001\/jamaoncol.2016.2214.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Las tecnolog\u00edas \u00f3micas son cruciales para seleccionar los pacientes oncol\u00f3gicos que pueden beneficiarse de los inhibidores que bloquean las v\u00edas inmunitarias relacionadas con CTLA-4 y PD-1. El tema es revisado en Dijkstra KK, Voabil P, Schumacher TN, Voest EE.\u00a0 Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Oncol. 2016; doi:10.1001\/jamaoncol.2016.2214.<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[19,21,22,23,29,39,32],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3334"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=3334"}],"version-history":[{"count":3,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3334\/revisions"}],"predecessor-version":[{"id":3344,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3334\/revisions\/3344"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=3334"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=3334"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=3334"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}